Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an ontario policy model

Ontario Health Technology Assessment Series

Volumn 12, Issue 12, 2012, Pages 1-61

  Chandra, K ^a   Blackhouse, G ^a   Mccurdy, B R ^a   Bornstein, M ^a   Campbell, K ^a   Costa, V ^a   Franek, J ^a   Kaulback, K ^a   Levin, L ^a   Sehatzadeh, S ^a   Sikich, N ^a   Thabane, M ^a   Goeree, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; INFLUENZA VACCINE; NICOTINE; PLACEBO; PNEUMOCOCCUS VACCINE;

ARTICLE; CANADA; CAREGIVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; HYPOXEMIA; INFLUENZA; LONG TERM CARE; MARKOV MODEL; MEDICAL DECISION MAKING; NICOTINE REPLACEMENT THERAPY; NONINVASIVE VENTILATION; OXYGEN THERAPY; PATIENT CARE; PATIENT COUNSELING; PNEUMOCOCCAL INFECTION; POSITIVE END EXPIRATORY PRESSURE; PULMONARY REHABILITATION; QUALITY OF LIFE; RESPIRATORY FAILURE; SMOKING CESSATION; STATISTICAL MODEL; SYSTEMATIC REVIEW (TOPIC); TELEMEDICINE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH POLICY; HUMANS; MODELS, STATISTICAL; ONTARIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84877012551     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76.
2. Saetta M, Di SA, Turato G, Facchini FM, Corbino L, Mapp CE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):822-6.
3. O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006 Dec;3(4):219-32.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. [place unknown]: Global Initiative for Chronic Obstructive Lung Disease; [updated 2010; cited 2011 Jul 6]. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf
5. Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008 Mar;102(3):413-21.
6. GRADE Working Group. Grading quality of evidence and strength of recommendations. Br Med J. 2006;328(7454):1490-4.
7. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65(8):711-8.
8. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J. 2010;35(1):79-87.
9. Drummond M, McGuire A. Economic evaluation in health care - merging theory with practice. New York: Oxford University Press Inc.; 2001.
10. Ontario Case Costing Initiative [Internet]. Toronto: Ontario Case Costing Initiative; [updated 2011 Jun; cited 2011 May]. Available from: http://www.occp.com/
11. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. Ottawa (ON); CADTH: 2006.
12. Rutten-van Molken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465-77.
13. Ringbaek T, Seersholm N, Viskum K. Standardised mortality rates in females and males with COPD and asthma. Eur Respir J. 2005 May;25(5):891-5.
14. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Molken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:435-44.
15. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ. 2007 Jun;8(2):123-35.
16. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-37.
17. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233-9.
18. Ontario drug benefit formulary [Internet]. Toronto: Ministry of Health and Long-Term Care (Ontario); [updated 2011 Apr 15; cited 2011 May]. Available from: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html
19. Compendium of pharmaceuticals and specialties (Canada). 44th ed. Ottawa (ON): Canadian Pharmacists Association; 2009.
20. Glaxosmithkline Nicorette Nicotine Gum 4mg Starter Kit 110 [Internet]. [updated 2011; cited 2011 Mar]. Available from: http://www.shopping.com/GlaxoSmithKline-Nicorette-Nicotine- Gum-4mg-Starter-Kit-110-GlaxoSmithKline/info
21. Schedule of benefits for physician services under the Health Insurance Act: effective March 24, 2010. Toronto: Ministry of Health and Long-Term Care (Ontario); 2010.
22. Guide to interdisciplinary provider compensation. Toronto: Ministry of Health and Long-Term Care (Ontario); 2011 May. Available from: http://www.health.gov.on.ca/transformation/fht/guides/fht_inter_provider.pdf
23. Brooks D, Sottana R, Bell B, Hanna M, Laframboise L, Selvanayagarajah S, et al. Characterization of pulmonary rehabilitation programs in Canada in 2005. Can Respir J. 2007;14(2):87-92.
24. Canadian classification of health interventions - ICD-10-CA/CCI. Ottawa (ON): Canadian Institute for Health Information; 2006.
25. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med. 2010 Mar 22;170(6):560-5.
26. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario [database online]. Toronto (ON): Ontario Ministry of Health and Long-Term Care; [updated 2008; cited 2011 May]. Available from: https://www.intellihealth.moh.gov.on.ca/
27. Lawati NA, FitzGerald JM. Acute exacerbation of chronic obstructive pulmonary disease. BC Med J. 2008;50(3):138-42.